Literature DB >> 29253177

Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI).

Holger Eggebrecht1,2, Beatriz Vaquerizo3, Cesar Moris4, Eduardo Bossone5, Johannes Lämmer1, Martin Czerny6, Andreas Zierer7, Holger Schröfel6, Won-Keun Kim8, Thomas Walther8, Smita Scholtz9, Tanja Rudolph10, Christian Hengstenberg11, Jörg Kempfert12, Marco Spaziano13, Thierry Lefevre13, Sabine Bleiziffer14, Joachim Schofer15, Julinda Mehilli16, Moritz Seiffert17, Christoph Naber18, Fausto Biancari19, Dennis Eckner20, Charles Cornet21, Thibault Lhermusier22, Raphael Philippart23, Antti Siljander24, Alfredo Giuseppe Cerillo25, Daniel Blackman26, Alaide Chieffo27, Philipp Kahlert28, Katarzyna Czerwinska-Jelonkiewicz29, Piotr Szymanski30, Uri Landes31, Ran Kornowski31, Augusto D'Onofrio32, Carl Kaulfersch33, Lars Søndergaard34, Darren Mylotte35, Rajendra H Mehta36, Ole De Backer34.   

Abstract

Aims: Life-threatening complications occur during transcatheter aortic valve implantation (TAVI) which can require emergent cardiac surgery (ECS). Risks and outcomes of patients needing ECS during or immediately after TAVI are still unclear. Methods and results: Incidence, risk factors, management, and outcomes of patients requiring ECS during transfemoral (TF)-TAVI were analysed from a contemporary real-world multicentre registry. Between 2013 and 2016, 27 760 patients underwent TF-TAVI in 79 centres. Of these, 212 (0.76%) patients required ECS (age 82.4 ± 6.3 years, 67.5% females, logistic EuroSCORE: 17.1%, STS-score 5.8%). The risk of ECS declined from 2013 (1.07%) to 2014 (0.70%) but remained stable since. Annual TF-TAVI numbers have more than doubled from 2013 to 2016. Leading causes for ECS were left ventricular perforation by the guidewire (28.3%) and annular rupture (21.2%). Immediate procedural mortality (<72 h) of TF-TAVI patients requiring ECS was 34.6%. Overall in-hospital mortality was 46.0%, and highest in case of annular rupture (62%). Independent predictors of in-hospital mortality following ECS were age > 85 years [odds ratio (OR) 1.87, 95% confidence interval (95% CI) (1.02-3.45), P = 0.044], annular rupture [OR 1.96, 95% CI (0.94-4.10), P = 0.060], and immediate ECS [OR 3.12, 95% CI (1.07-9.11), P = 0.037]. One year of survival of the 114 patients surviving the in-hospital period was only 40.4%.
Conclusion: Between 2014 and 2016, the need for ECS remained stable around 0.7%. Left ventricular guidewire perforation and annular rupture were the most frequent causes, accounting for almost half of ECS cases. Half of the patients could be salvaged by ECS-nevertheless, 1 year of all-cause mortality was high even in those ECS patients surviving the in-hospital period. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2018        PMID: 29253177     DOI: 10.1093/eurheartj/ehx713

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement.

Authors:  Harun Kundi; Jeffrey J Popma; Kamal R Khabbaz; Louis M Chu; Jordan B Strom; Linda R Valsdottir; Changyu Shen; Robert W Yeh
Journal:  JAMA Cardiol       Date:  2019-01-01       Impact factor: 14.676

Review 2.  Transcatheter aortic valve implantation in Germany.

Authors:  Won-Keun Kim; Christian W Hamm
Journal:  Clin Res Cardiol       Date:  2018-06-27       Impact factor: 5.460

Review 3.  Cardiac surgery 2017 reviewed.

Authors:  Torsten Doenst; Hristo Kirov; Alexandros Moschovas; David Gonzalez-Lopez; Rauf Safarov; Mahmoud Diab; Steffen Bargenda; Gloria Faerber
Journal:  Clin Res Cardiol       Date:  2018-05-17       Impact factor: 5.460

4.  Mechanically expanding transcatheter aortic valves: pros and cons of a unique device technology.

Authors:  Kenan Yalta; Muhammet Gurdogan; Cafer Zorkun; Yekta Gurlertop
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

5.  Cochlear Implant Outcome Reviews.

Authors:  Jameel Muzaffar; Peter Monksfield; Manohar Bance
Journal:  J Int Adv Otol       Date:  2020-12       Impact factor: 1.017

Review 6.  The Lotus Valve System: an In-depth Review of the Technology.

Authors:  Matthew E Seigerman; Ashwin Nathan; Saif Anwaruddin
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 7.  Annular Rupture During Transcatheter Aortic Valve Implantation: Predictors, Management and Outcomes.

Authors:  J J Coughlan; Thomas Kiernan; Darren Mylotte; Samer Arnous
Journal:  Interv Cardiol       Date:  2018-09

8.  Relationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes.

Authors:  Sameer A Hirji; Ellen McCarthy; Dae Kim; Siobhan McGurk; Julius Ejiofor; Fernando Ramirez-Del Val; Ahmed A Kolkailah; Bernard Rosner; Douglas Shook; Charles Nyman; Natalia Berry; Piotr Sobieszczyk; Marc Pelletier; Pinak Shah; Patrick O'Gara; Tsuyoshi Kaneko
Journal:  JACC Cardiovasc Interv       Date:  2020-02-10       Impact factor: 11.195

9.  Impact of device landing zone calcification patterns on paravalvular regurgitation after transcatheter aortic valve replacement with different next-generation devices.

Authors:  Victor Mauri; Thomas Frohn; Florian Deuschl; Kawa Mohemed; Kathrin Kuhr; Andreas Reimann; Maria Isabel Körber; Niklas Schofer; Matti Adam; Kai Friedrichs; Elmar W Kuhn; Smita Scholtz; Volker Rudolph; Thorsten C W Wahlers; Stephan Baldus; Navid Mader; Ulrich Schäfer; Tanja K Rudolph
Journal:  Open Heart       Date:  2020-05

10.  Relationship between procedural characteristics and cerebrovascular events after transcatheter aortic valve replacement.

Authors:  Kashish Goel; Vuyisile T Nkomo; Joshua P Slusser; Ryan Lennon; Robert D Brown; Kevin L Greason; David R Holmes
Journal:  Open Heart       Date:  2018-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.